The Polypill: From Promise to Pragmatism

* Starting with the promise and a brief history of the polypill, this article considers its current status and highlights five pragmatic issues to address before the polypill can become a mainstream strategy.

Saved in:
Bibliographic Details
Published in:PLoS medicine Vol. 12; no. 8; p. e1001862
Main Author: Huffman, Mark D.
Format: Journal Article
Language:English
Published: United States Public Library of Science 01.08.2015
Public Library of Science (PLoS)
Subjects:
Analysis
Blood pressure
Cardiovascular Agents - administration & dosage
Cardiovascular disease
Cardiovascular Diseases - prevention & control
Clinical medicine
Clinical trials
Clinical Trials as Topic
Collaboration
Disease prevention
Drug dosages
Enzymes
Funding
Heart attacks
HIV
Human immunodeficiency virus
Humans
Medication Adherence
Pharmaceutical industry
Pragmatism
Primary Prevention
Quality
Secondary Prevention - methods
Statins
United States
United States Food and Drug Administration
Writers
United States
ISSN:1549-1676, 1549-1277, 1549-1676
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:* Starting with the promise and a brief history of the polypill, this article considers its current status and highlights five pragmatic issues to address before the polypill can become a mainstream strategy.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
I have read the journal's policy and have the following conflicts: I receive grant support from the World Heart Federation as senior program advisor for its Emerging Leaders program, which has received funding from AstraZeneca in the past and is current supported by Boehringer Ingelheim and Bupa, which are not manufacturers of fixed-dose combination therapy. I have led the 2012 and 2014 applications to the World Health Organization’s Model List of Essential Medicines for inclusion of fixed-dose combination therapy for the secondary prevention of cardiovascular diseases. I am also the senior author of the 2014 Cochrane systematic review on fixed-dose combination therapy and coordinating editor of the Cochrane Heart Group US Satellite at Northwestern. I also receive grant support from the National Heart, Lung, and Blood Institute for heart attack quality improvement clinical trial and from the National Cancer Institute for a smoking cessation clinical trial. I have also received travel support from the Cochrane Collaboration (Heart Group), American Heart Association, and World Heart Federation in the past two years.
Wrote the first draft of the manuscript: MDH. Contributed to the writing of the manuscript: MDH. Agree with the manuscript’s results and conclusions: MDH. The author has read, and confirms that he meets, ICMJE criteria for authorship.
ISSN:1549-1676
1549-1277
1549-1676
DOI:10.1371/journal.pmed.1001862